Delcath Systems, Inc
Delcath Systems is a U.S.-based interventional oncology company focused on treating cancers that are primary to, or have spread to, the liver. Its core commercial product is HEPZATO KIT, a drug/device combination therapy approved for adult patients with unresectable hepatic metastases from uveal melanoma, and the company also markets CHEMOSAT in Europe.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueApproved liver-directed therapies sold for use in eligible cancer patients.
CHEMOSAT-based treatment used in Europe for hepatic-dominant cancer care.
Research and trials aimed at expanding HEPZATO into additional indications.
Products
Reported · share of revenue- HEPZATOKIT92.5 %
- CHEMOSAT7.5 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Delcath sells primarily to hospitals, cancer centers, and interventional oncology facilities that treat patients with liver-dominant metastatic disease. Demand is driven by specialist physicians and treatment centers that can perform the procedure and manage complex oncology patients. In the U.S., commercialization depends on physician adoption and facility access, while in Europe the customer base includes centers using CHEMOSAT under local market and reimbursement conditions.
Buy and use HEPZATO KIT for eligible adult patients with unresectable hepatic metastases from uveal melanoma.
Use CHEMOSAT for liver-directed cancer treatment in markets where the system is commercialized.
Oncologists and interventional radiologists refer patients and drive adoption by educating eligible patients.
Participate in studies for new indications such as mCRC and mBC to expand future use cases.
Strategy
Delcath’s strategy is to build HEPZATO into a durable commercial franchise in the U.S. while sustaining CHEMOSAT demand in Europe. The company is also investing in clinical expansion, including trials in metastatic colorectal cancer and breast cancer, to broaden the addressable market beyond uveal melanoma. Commercial execution, physician education, and reimbursement access are central to turning the approved product into repeatable sales.
The product is approved and first commercial use began in 2024, so scaling utilization is the main near-term value driver.
Additional indications could materially enlarge the market and reduce dependence on a single rare-cancer franchise.
Europe provides a second commercial channel and diversifies the company’s revenue base.
Geography
Q2/2026Delcath is headquartered in Queensbury, New York and commercializes HEPZATO in the United States while also selling CHEMOSAT in Europe. The company’s growth is tied to U.S. physician adoption and reimbursement, but its European presence adds exposure to different healthcare systems, pricing rules, and regulatory requirements. Manufacturing and outsourced support activities are not fully detailed in the excerpts, but the business relies on consultants and third parties for marketing, quality, manufacturing, and corporate services.
Share of the revenue the company reports by geography.
Risks
Delcath remains exposed to commercialization risk because HEPZATO is a newly launched specialty product and adoption depends on physician access, reimbursement, and treatment-center capacity. The business also faces regulatory, intellectual property, and cybersecurity risks, while its small scale makes it sensitive to execution missteps, clinical trial outcomes, and cash burn. Because the company relies on third parties for parts of its operating model, supply-chain and vendor performance are also important.
- Commercial adoption risk for HEPZATOImpact: HighLikelihood: Medium
Revenue depends on a limited number of specialist centers and physician uptake of a new therapy.
Exposure: U.S. commercialization and treatment-site expansion
- Reimbursement and pricing pressureImpact: HighLikelihood: Medium
Healthcare consolidation and payor rules can force discounts or restrict utilization.
Exposure - Clinical development failureImpact: HighLikelihood: Medium
Future growth depends on successful trials in mCRC and mBC and other indications.
Exposure: Pipeline expansion programs
- Intellectual property protectionImpact: MediumLikelihood: Medium
Weak patent or trade secret protection could allow competitors to copy the technology.
Exposure: HEPZATO and CHEMOSAT technology
- Cybersecurity and third-party dependencyImpact: MediumLikelihood: Medium
The company relies on consultants and external systems, increasing operational vulnerability.
Exposure
Accounting
Judgemental itemsHEPZATO sales are affected by statutory rebates, 340B pricing, and VA ceiling prices.
Impact: Net revenue can differ materially from gross product sales.
The company has issued and exercised warrants, which can affect earnings and equity accounts.
Impact: Non-cash gains or losses may create volatility in other income/expense.
Employee and director equity awards are used to attract and retain talent.
Impact: Raises operating expense and can materially affect reported losses.
Trial and regulatory spending is largely expensed as incurred.
Impact: R&D expense can swing with trial initiation and headcount changes.
Similar listed companies
Publicly listed companies with a comparable business focus.
Hepion Pharmaceuticals, Inc.
HEPA · Pharmaceutical Preparations
Gilead Sciences, Inc
GILD · Biological Products, (No Diagnostic Substances)
Gilead Sciences is a U.S.-based biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious diseases.
Decoy Therapeutics Inc.
DCOY · Pharmaceutical Preparations
Tempest Therapeutics, Inc.
TPST · Pharmaceutical Preparations
RenovoRx, Inc.
RNXT · Surgical & Medical Instruments & Apparatus
Autolus Therapeutics plc
AUTL · Biological Products, (No Diagnostic Substances)
Autolus Therapeutics plc is a biopharmaceutical company focused on developing and commercializing programmed T-cell therapies, with its first approved product, AUCATZYL, now generating U.S.
Last updated: 24/09/2026